HelicsWin.Net (also referred to as HWN) is a software application developed for the manual entry of data of the ECDC HAI-Net surveillance of healthcare-associated infections (HAIs).
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
The ECDC HIV Platform Tool is a new end-user application that uses statistical and mathematical methods to calculate adjusted estimates from HIV surveillance data, considering the issues of missing data and reporting delay and employing modelling techniques.
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.